Caliper LS Awarded National Institute of Environmental Health Services Contract Valued to $7 Million
News Oct 04, 2007
Caliper Life Sciences, Inc. has announced that the National Institute of Environmental Health Services (NIEHS) has awarded the company a contract valued at up to $7.0 million covering a period of up to ten years at the option of NIEHS.
Under the terms of the agreement, Xenogen Biosciences, the in vivo drug discovery services arm of Caliper Discovery Alliances & Services (CDAS), will supply numerous NIEHS investigators with genetically-modified mouse models for research purposes.
The NIEHS focuses its research on the environment and its impact on human health and disease. Working with genetically modified mouse models, including transgenic and gene knockout, enables NIEHS to conduct research aimed at identifying and potentially preventing hazardous conditions and exposure in humans. Beginning immediately, Caliper will develop unique mouse models based on the needs of the research teams at the NIEHS.
The business was awarded to Caliper through a competitive bid process and reflects the company's expertise and ability to design and produce genetic modifications in mice. Caliper has produced more than 9,000 mouse and rat models, some of which were previously supplied to the NIEHS under the terms of a previous multi-year agreement.
"This contract is the second significant win for our services business in recent months, following the in vitro Environmental Protection Agency contract announced earlier in the second quarter," said Kevin Hrusovsky, CEO of Caliper Life Sciences. "Our contract with the NIEHS builds on our existing relationship with this organization and further validates the capabilities of our services organization and the increasing industry demand that is fueling our growth."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.